Financing of growth companies within life science

What we offer

Sciety provides the entire project management of the process from production of presentation material to the funds arriving in your account. We initiate cooperation by identifying your requirements and establishing a time plan. Based on our specialist competence in life science and a structured approach, we contribute with an in-depth understanding of your operations, as well as expertise in the most efficient means of achieving your goals. Sciety assists in producing investment material, communication with investors and the administration of the investments.

Contact us for more information

Are we a good match?

Sciety focuses on prominent companies within biotechnology, digital health, pharmacology, ICT in healthcare and medical technology seeking to raise SEK 10-100 million. The companies’ development phase depends on the area and innovation level. Pharmaceutical companies should be in the late preclinical phase or early clinical phase, while companies within digital health should have an initial user base. Sciety has a structured process for selecting and reviewing companies in which business potential and medical and legal aspects are analysed.

What our clients think

“As founder and SEO, I am very satisfied with Sciety’s services. With a friendly approach and exceptional business development skills, Sciety educated and trained us to reach our goals. Sciety provided investments and invaluable expertise for EMPE Diagnostics which develops rapid diagnostic solutions for antibiotic resistance with a special focus on tuberculosis. I highly recommend Sciety."

Pavan Asalapuram, CEO of EMPE Diagnostics

“Sciety offers a professional and structured way to access financing at an early stage. Life science projects are often difficult to analyse; therefore, Sciety’s focus on this segment is positive for both companies seeking financing and for investors looking for new investment possibilities.”

Fredrik Sjövall, CEO of Inhalation Sciences

“Athera chose to work with Sciety as they have an effective process for capital acquisition combined with specialist competence within life science and a strong network of investors. With the help of Sciety, Athera could execute their share issue in a short amount of time. Both management and owners are very satisfied with the cooperation with Sciety.”

Carina Schmidt, CEO of Athera Biotechnologies

"Sciety provided valuable expertise and with their structured way of working they took responsibility for all the necessary agreements, planning and project management that was needed in the fundraising. Investments from their syndicate gave Predicare access to capital that now enables our broader expansion in Europe and further development of our product portfolio."

Mathias Myrén, CEO of Predicare

"I am very pleased with the cooperation and our successful funding round with Sciety. Despite the current situation with the Covid-19 pandemic, which significantly affects the willingness to invest, Sciety quickly managed to raise the capital. We are happy for the great interest in our unique treatment and welcome our new shareholders."

Fredrik Lehman, Chairman of the Board and Co-Founder of Synartro

"Sciety supported us in all parts of the financing process in an excellent way. In addition to the professional contact with relevant investors, I particularly appreciated the flexibility and drive of the process. The outcome was also very good with a fully funded business plan and a strong group of new partners who share our vision."

Karl Bergman, CEO of Elypta

"The Sciety team is professional with a rare blend of expertise in life science, finance and entrepreneurship. We appreciated their general expertise and in particular their advice on pitching and marketing and in negotiation with investors. Their network of investors is of great value for high tech companies such as Attana. Thanks to our fundraising with Sciety, we have also gained new valuable competence in our board."

Teodor Aastrup, CEO of Attana

Communication with the capital markets

What we offer

Sciety works proactively to highlight the company to potential investors and to strengthen the relationship with the company’s existing shareholders. Based on our experience in life science and digital communication, we transform complex information into effective communication. Our communication packages include design and distribution of press releases, communication in social media and digital channels, website design and implementation of analysis tools.

Get in touch with us. We are happy to provide you with more information.

Are we a good match?

In the growth phase the core operations often receive all of the focus and it can be difficult to find time for communication. At the same time, relevant and continual communication is something which investors value notably. Our communications package is aimed at companies wishing to build up long-term relationships in the capital market in order to facilitate future capital acquisition. These services are appropriate for small and medium-sized companies within life science where there is a need of external capital within a three-year period.

What our clients think

“Sciety took care of all communication in conjunction with securing capital for our company. Their understanding of life science and finance made it possible for us to produce relevant and clear content in press releases and similar communication.

Through Sciety’s channels we received market exposure in, among other places, Dagens Industri’s web page, something that was very valuable”.

Carina Schmidt, CEO of Athera Biotechnologies